Hepatocellular Carcinoma Clinical Trial
Official title:
"Pilot Study: Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway in the Management of a Patient Treated for Hepatocellular Carcinoma (HCC)"
This project is based on the assumption that the nurse coordinators of the centres have
common missions at each of the key stages of patient care. These missions make the care plan
more fluid and improve the quality and safety of care as well as the patient's prognosis.
The Hypothesis is that co-follow-up by a doctor and a nurse coordinator reduces time between
referral to treatment, average lengths of stay, unscheduled readmissions or early emergency
visits, compared to follow-up that does not involve a nurse coordinator.
Main objective:
Describe the roles and missions of professionals dedicated to the coordination of care
pathways for patients with HCC
Secondary objectives:
Compare the indicators of quality of care in HCC centres with a nurse coordinator:
1. Timeframe in treatment:
- timeframe between the first contact with the HCC centre and the first
interventional radiology treatment.
- timeframe between the first contact with the centre and the first presentation at a
multidisciplinary team meeting (MDT)
- time between the first contact with the centre and the diagnostic consultation
- timeframe between the first contact with the centre and discharge from the hospital
- timeframe between the first interventional radiology procedure and the next for the
subgroup of patients who have multiple procedures during the follow-up period
- timeframe between the first contact with the nurse coordinator of the centre and
discharge from the hospital.
2. The average length of stay of hospitalization
3. The number of visits to the emergency unit during the first month following the
radiology intervention
4. The number of unscheduled readmissions during the first month following the
intervention.
Assess the feasibility of collecting the above-mentioned timeframe and variables and the
patients and carers feedback on the coordination of the care pathway Describe the
organization of care pathways for patients with HCC in centres with or without a nurse
coordinator.
Research method: This is a retrospective descriptive pilot study. It aims to describe the
organization of care.
Population: Patient with a diagnosis of localized hepatocellular carcinoma.
Data processing:
- Feasibility questionnaires will be sent by email.
- The interviews will be transcribed and coded with NVivo® software
- Patient data will be collected in the ecrf
- Data processing from anonymized files by the authors of the research only. All data will
be centralized at Bichat Hospital (URC Paris Nord) for statistical analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 | |
Recruiting |
NCT05537402 -
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
|
Phase 2 |